News

Upsher-Smith Unveils Innovations at Annual Neurology Conference

Upsher-Smith Unveils Innovations at Annual Neurology Conference

Upsher-Smith Showcases Innovations at Major Neurology Conference

Upsher-Smith Laboratories, LLC, a trusted name in pharma, is excited to share its innovations at the upcoming major annual meeting of the American Academy of Neurology (AAN). The company is set to present its expanding portfolio tailored for rare diseases, particularly focusing on their flagship product, VIGAFYDE™. This is particularly notable, as VIGAFYDE™ stands out as the first and only ready-to-use liquid vigabatrin solution, aimed specifically at addressing the critical needs of infants diagnosed with infantile spasms.

Introduction of VIGAFYDE™ Oral Solution

VIGAFYDE™ (vigabatrin) Oral Solution is a pivotal development as it is intended for infants aged between 1 month to 2 years. Administered as a monotherapy, its design aims to mitigate the potential risks associated with vision loss. This formulation promises to streamline the medication process, making it easier for caregivers while maximizing effectiveness.

Commitment to Rare Diseases

Upsher-Smith's commitment to the rare disease community remains steadfast and is evident in their robust product offerings, including VIGADRONE® (vigabatrin) Tablets and TORPENZ™ (everolimus) Tablets. The journey for healing and treatment for patients relies heavily on continued innovation and support which Upsher-Smith is determined to provide. Jim Maahs, Head of Commercial at Upsher-Smith, noted that their offerings have significantly expanded since the launch of VIGADRONE® in 2018. Their booth at the conference will be buzzing with rich discussions about these crucial innovations and the future of patient treatments.

The Promise of Support™ Program

Further illustrating their dedication, Upsher-Smith's Promise of Support™ Program provides indispensable resources for patients and healthcare providers alike. This program covers various elements crucial for the continuous support of patients prescribed VIGADRONE®, including assistance with copays for eligible patients, ensuring that financial constraints do not pose a barrier to necessary treatment.

Engagement at the Conference

At the AAN Annual Meeting, Upsher-Smith representatives will be readily available to engage with medical professionals, providing insights into their offerings. Visitors can expect to learn about advanced treatment options, including the unique benefits of VIGAFYDE™ alongside ongoing support programs for patients, caregivers, and healthcare professionals. The interactive experiences at their booth promise to be enlightening, encouraging open dialogue regarding the challenges and solutions in the realm of rare diseases.

Safety Information Regarding VIGAFYDE™

While VIGAFYDE™ represents a significant advancement in the management of infantile spasms, it is imperative to discuss the associated risks. A Risk Evaluation and Mitigation Strategy (REMS) governs all vigabatrin products, underscoring the importance of informed decisions regarding treatment options. Continuous vision monitoring is crucial, and all prescribing healthcare providers must be part of the REMS program to ensure patient safety.

Upsher-Smith: An Overview

In alignment with their commitment to continuous growth and innovation, Upsher-Smith is proud to be a member of the Bora Group, enhancing their capabilities and outreach. Known for a stable supply chain and a strong focus on customer service, Upsher-Smith is fundamentally about improving the health outcomes of patients worldwide.

Frequently Asked Questions

What is VIGAFYDE™?

VIGAFYDE™ is a ready-to-use oral solution of vigabatrin indicated for the treatment of infantile spasms in children.

Where can I find Upsher-Smith's products?

Upsher-Smith's products, including VIGAFYDE™, are available through various healthcare providers and pharmacy partners.

What is the Promise of Support™ Program?

The Promise of Support™ Program offers comprehensive resources, including financial assistance for patients prescribed VIGADRONE®.

How can patients ensure they are monitored while using VIGAFYDE™?

Regular vision testing and engagement with a healthcare provider are vital components of care while using VIGAFYDE™.

What other products does Upsher-Smith offer?

In addition to VIGAFYDE™, Upsher-Smith offers VIGADRONE® Tablets and TORPENZ™ Tablets for the treatment of various conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 101

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 96

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 183

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 49

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 217

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 131

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading

Top 5 Most Recently Viewed Articles

Voltalia Partners with Retail Giants for EV Charging Stations

Updated Category News Views 165

Innovative Partnership to Enhance Electric Vehicle Charging Voltalia, a prominent name in the renewable energy sector, is making significant strides by collaborating with Auchan, DECATHLON, and Leroy Merlin. This partnership aims to deploy electric vehicle (EV) charging stations across more than 350 parking lots in France, marking a crucial step towards fostering...

Continue Reading
Khanh Phuong Morrow's Strategic Insider Move at Lantheus Holdings

Updated Category News Views 211

Khanh Phuong Morrow's Strategic Insider Decision at Lantheus Holdings In a recent filing, it was disclosed that Khanh Phuong Morrow, a Board Member at Lantheus Holdings (NASDAQ: LNTH), exercised stock options leading to a transaction valued at $0. This decision sheds light on the ongoing activities within the company and showcases the actions of key insiders....

Continue Reading
Investors Urged to Stay Informed on Organon & Co. Class Action

Updated Category News Views 170

Class Action Lawsuit Against Organon & Co. Pomerantz LLP has announced the initiation of a class action lawsuit against Organon & Co. This lawsuit primarily targets investors who have suffered losses relating to their investment in Organon (NYSE: OGN). With the launch of this lawsuit, it is essential for affected investors to understand their rights and options available...

Continue Reading
Sionna Therapeutics Faces Legal Scrutiny Amid Stock Plunge

Updated Category News Views 90

Stock Drop Sparks Legal Action August 10, 2026, wasn't exactly a banner day for Sionna Therapeutics' investors. We're talking about watching a stock nosedive by a jaw-dropping 92%, which is the kind of number that'd knock your socks off under normal circumstances. The catalyst? Some dismal results from the company's Phase 2a proof-of-concept study of SION-719 aimed at...

Continue Reading
Toll Brothers Unveils Stunning New Homes in Chapel Oaks

Updated Category News Views 221

Exciting New Model Homes at Chapel Oaks Community CHAPEL HILL, N.C. – Toll Brothers, Inc. (NYSE: TOL), a prominent name in luxury home construction, has recently announced the opening of their latest model home at the Chapel Oaks community. This new community marks a significant addition to their portfolio in the Raleigh area, providing prospective homeowners with...

Continue Reading